OECD Health Working Papers

ISSN :
1815-2015 (online)
DOI :
10.1787/18152015
Hide / Show Abstract
This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language - English or French - with a summary in the other.
 

Value in Pharmaceutical Pricing You or your institution have access to this content

Click to Access: 
    http://oecd.metastore.ingenta.com/content/5k43jc9v6knx.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en
  • READ
Author(s):
Valérie Paris1, Annalisa Belloni1
Author Affiliations
  • 1: OECD, France

Publication Date
11 July 2013
Bibliographic information
No.:
63
Pages
74
DOI
10.1787/5k43jc9v6knx-en

Hide / Show Abstract

This study analyses how 14 OECD Countries refer to "value" when making decisions on reimbursement and prices of new medicines. It details the type of outcomes considered, the perspective and methods adopted for economic evaluation when used; and the consideration of budget impact. It describes which dimensions are taken into account in the assessment of "innovativeness" and the consequences of this assessment on prices; it confirms that treatments for severe and/or rare diseases are often more valued than others and shows how countries use product-specific agreements in an attempt to better align value and price.
JEL Classification:
  • I18: Health, Education, and Welfare / Health / Government Policy; Regulation; Public Health